Abstract: The present invention relates to antibodies against human CSF-1R (CSF-1R antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present disclosure relates to AM-14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.

Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.

Abstract: Disclosed in the present invention is an antibody specifically binding to GLP-1R and a fusion protein thereof with GLP-1. The fusion proteins can effectively bind to a human GLP-1R receptor and activate a receptor signaling pathway, thus are useful for treating diabetes, excessive weight, obesity and related disorders thereof.

Abstract: The invention provides methods of treating or delaying progression of cancer in an individual comprising administering to the individual an anti-human OX40 agonist antibody. In some embodiments, the antibody is administered in a dose selected from about 0.2 mg, about 0.8 mg, about 3.2 mg, about 12 mg, about 40 mg, about 80 mg, about 130 mg, about 160 mg, about 300 mg, about 320 mg, about 400 mg, about 600 mg, and about 1200 mg.

Abstract: The present invention comprises human monoclonal antibodies that bind to PD-L1 (also known as programmed death ligand 1 or B7H1). Binding of the invented antibody to PD-L1 inhibits binding to its receptor, PD1 (programmed death 1), and ligand-mediated activities and can be used to treat cancer and chronic viral infections.

Abstract: The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

Abstract: Described herein are compositions, methods, and systems for modulating Notch receptor activation. Aspects of the invention relate to synthetic proteins comprising at least a Notch NRR (Negative Regulatory Region)-binding scFV fused to a transmembrane domain. Another aspect of the invention relates to drug-dependent synthetic proteins. Constructs and engineered cells comprising the synthetic proteins are additionally described herein.

Abstract: In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order VLA-VHB-VLB-VHA from the N-terminal to the C-terminal of the polypeptide. Compositions of the antigen-binding molecule and the methods of using the antigen-binding molecule or the compositions thereof for treatment of various diseases are also provided herein.

Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells.

Abstract: The present invention relates to an antibody specifically binding to glypican 3 (GPC3), a nucleic acid encoding the antibody, a vector and a host cell containing the nucleic acid, a method of preparing the antibody, and a pharmaceutical composition for treating cancer or tumor, containing the antibody as an active ingredient. The antibody specifically binding to glypican 3 according to the present invention may be effectively used to treat cancer or tumor, particularly, hepatocellular carcinoma due to high affinity and specificity to glypican 3.

Abstract: The present disclosure provides novel anti-OX40 antibodies, compositions including the antibodies, nucleic acids encoding the antibodies, and methods of making and using the same.

Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.

Abstract: The present invention provides a cell which comprises a first chimeric antigen receptor (CAR) and a second CAR, wherein the first and second CARs bind different epitopes on the same ligand. The cell may be used in a method for treating a disease, such as cancer.

Abstract: Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.

Abstract: The present invention provides compositions for the production of an antibody or functional fragment thereof directed against disialoganglioside-GD2. The compositions of the invention include polynucleotides encoding a heavy chain and/or a light chain variable domain that binds to GD2. The invention also provides an isolated antibody or functional fragment thereof and methods of treating or preventing a disease, such as cancer or tumor formation, wherein the antibody or functional fragment includes a variable heavy chain domain and a variable light chain domain that has an amino acid sequence provided herein. The invention further provides a conjugate of an antibody or functional fragment thereof conjugated or recombinantly fused to a diagnostic agent, detectable agent or therapeutic agent, and methods of treating, preventing or diagnosing a disease in a subject in need thereof.

Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

Abstract: Mice are provided that comprise a reduction or deletion of ADAM6 activity from an endogenous ADAM6 locus, or that lack an endogenous locus encoding a mouse ADAM6 protein, wherein the mice comprise a sequence encoding an ADAM6 or ortholog or homolog or fragment thereof that is functional in a male mouse. In one embodiment, the sequence is an ectopic ADAM6 sequence or a sequence that confers upon a male mouse the ability to generate offspring by mating. Mice and cells with genetically modified immunoglobulin heavy chain loci that comprise an ectopic nucleotide sequence encoding a mouse ADAM6 or functional fragment or homolog or ortholog thereof are also provided.

Abstract: A method for evaluating and screening a mutant inducing the high-efficiency formation of heterodimers from a human antibody heavy chain constant region mutant pair combination library in order to increase the yield of formation of human antibody heterodimeric heavy chain constant regions. A heterodimeric heavy chain constant region (heterodimeric F) library is obtained by the method. A CH3 domain mutant pair, in which the formation of the heterodimeric heavy chain constant regions is preferred in the library, forms heterodimeric heavy chain constant regions at a high yield of at least 80-90%, and also has excellent thermal stability and retains binding ability to the heavy chain constant region receptor (FcRn).

Abstract: The present invention provides antibodies that specifically bind to FLT3 (Fms-Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).

Abstract: The invention provides anti-variant Fc-region antibodies which specifically bind to an antibody that has the mutation P329G or the mutations P329G/L234A/L235A or the mutations I253A/H310A/H435A in the Fc-region, and methods of using the same.

Abstract: The present invention relates to heterodimerically-tethered bispecific protein complexes (according to the general formula of A-X:Y-B) and libraries/multiplexes thereof for use in research and therapy and in particular an in vitro/ex vivo method of detecting synergistic biological function of otherwise unknown pairs of targets.

Abstract: The present invention relates to a method of identifying, separating and characterizing a cell or a population of cells, by capturing at the cell surface, secreted soluble substances (such as an immunoglobulin) that cell or population of cell secrete. This is achieved by combing on a heterodimerically-tethered multispecific protein complex combining a binding specificity for the secreted molecule and a binding specificity for a surface antigen specific for that cell or population of cells. This method may be used in research and experimental purposes, such as patients' stratification in preparation of clinical trials or personalized therapies by identifying cell populations relevant to a pathology and/or prognosis.

Abstract: The present invention relates to engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations and methods of making and using them.

Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.

Abstract: The present disclosure relates to the environmentally preparation of nanocellulose and derivatives thereof. The invention further relates to the preparation of cellulose derivatives.

Abstract: The present application provides crystalline forms of 6-per-deoxy-6-per-chloro-?-cyclodextrin, and polymorphs thereof. The present application also provides methods for preparing said polymorphs by dissolving 6-per-deoxy-6-per-chloro-?-cyclodextrin in dimethylformamide and using an anti-solvent of a water/alcohol mixture.

Abstract: The present invention related to low-chloride alkylated cyclodextrin compositions, along with processes for preparing and using the same. The processes of the present invention provide alkylated cyclodextrins with low levels of drug-degrading agents and chloride.

Abstract: Disclosed are methods and conditions for manufacturing a polyethylene polymer or copolymer in a liquid/liquid biphasic non-adiabatic reaction, and the compositions and articles made therefrom.

Abstract: A coating including a composition of 5% to 10% by weight of water, 5% to 20% by weight of silica sol, 0.05% to 0.2% by weight of KH-560 silane coupling agent, and 20% to 60% by weight of quartz powder is disclosed. The forming method for the coating includes mixing the water, the silica sol, and the KH560-silane coupling agent into a decomposing agent; adding a wetting agent, phthalein white powder, modified bentonite, quartz powder, and a styrene-acrylate emulsion or a pure acrylate emulsion into the decomposing agent to form a mixing agent; adding a carboxymethyl cellulose, a crosslinking agent, a fungicide and a deodorant into the mixing agent to form a thickened mixing agent; and adding a deforming agent into the thickened mixing agent to form the coating. The quartz coating has advantages of effectively improve living environment and good covering ability.

Abstract: The present invention is directed to a process for separating hydrocarbons from a solution comprising a polymer. The process comprises the steps of: (A) withdrawing a solution stream comprising the polymer from a first vessel; (B) passing the solution stream into a flash vessel; (C) spraying the solution stream into droplets in the first flash vessel thereby establishing a stream of droplets within the flash vessel. The solution forms a downwards falling film within the flash vessel.

Abstract: The invention provides a process to prepare an ethylene-based polymer, said process comprising polymerizing ethylene in the presence of at least one initiator system selected from the following: a) class 1 initiator system, b) class 2 initiator system, c) class 3 initiator system, or d) a combination thereof; and at a inlet pressure (P2) greater than, or equal to, 1000 Bar (100 MPa); and in a reactor system comprising at least one hyper compressor and a reactor configuration comprising at least one reactor, which comprises at least one reaction zone; and wherein the inlet pressure (P2) is reduced by at least 200 Bar, as compared to a similar polymerization, in the same reactor system, except it is operated at a higher inlet pressure (P1), and at a different hyper compressor throughput, and at a different maximum temperature for at least one reaction zone, and optionally, at a different amount of CTA system fed to the reactor configuration; and wherein, for the process, the “Ratio of total reactor consumption

Abstract: A polymerizable composition excellent in solubility and having high storage stability with no crystal precipitation or the like; a polymerizable composition capable of being formed into a polymer excellent in alignment performance and leveling performance, hardly having defects, cissing and unevenness and hardly causing appearance failure owing to surfactant offset; and a polymer, an optically anisotropic body, a display element, a light-emitting element and the like using the polymerizable composition are provided. Specifically, the invention provides a polymerizable composition containing a) one or two or more polymerizable compounds each having one polymerizable group or two or more polymerizable groups and satisfying a formula (I) Re(450 nm)/Re(550 nm)<1.0 (I), and b) one or two or more compounds represented by the general formula (B).

Abstract: The present invention provides multifunctional monomers, including, but not limited to include multifunctional methylene malonate and methylene beta-ketoester monomers; methods for producing the same; and compositions and products formed therefrom. The multifunctional monomers of the invention may be produced by transesterification or by direct synthesis from monofunctional methylene malonate monomers or methylene beta-ketoester monomers. The present invention further compositions and products formed from methylene beta-ketoester monomers of the invention, including monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

Abstract: The present invention provides a modifier, a modified and conjugated diene-based polymer which is modified using the same, and a rubber composition including the modified and conjugated diene-based polymer, and more particularly, a modifier which includes a compound represented by Formula 1 and is capable of improving the mixing properties between a conjugated diene-based polymer and a filler, a modified and conjugated diene-based polymer which is modified using the same, and a rubber composition including the modified and conjugated diene-based polymer.

Abstract: The use of a diene elastomer and of a 1,3-dipolar compound in a rubber composition based at least on a reinforcing filler comprising a reinforcing inorganic filler and on a coupling agent is provided. The 1,3-dipolar compound comprises a group Q and a group A connected together by a group B, in which Q comprises a dipole containing at least one nitrogen atom, A comprises an associative group comprising at least one nitrogen atom and B is an atom or a group of atoms forming a bond between Q and A. The diene elastomer is obtained by stereospecific polymerization of at least one 1,3-diene by means of a Ziegler-Natta catalytic system and containing less than 150 ppm of the element neodymium. The use of such a diene elastomer and such a 1,3-dipolar compound in the rubber composition makes it possible to confer a very low hysteresis on the rubber composition.

Abstract: A process for preparing a long chain branched polypropylene in presence of two metallocene-based active catalyst systems is provided. The polypropylene obtained therefrom has new molecular architecture and improved elasticity properties. The polypropylene is further characterized by new signals in its 13C NMR spectrum.

Abstract: A flame-retardant aconitic acid-derived monomer, a process for forming a flame-retardant polymer, and an article of manufacture comprising a material that contains a flame-retardant aconitic acid-derived monomer are disclosed. The flame-retardant aconitic acid-derived monomer can have at least one phosphoryl or phosphonyl moiety with functional groups that can participate in a polymerization reaction, such as allyl, epoxy, or propylene carbonate functional groups. The process for forming the flame-retardant polymer can include forming an aconitic acid derivative, forming a phosphorus-based flame-retardant molecule, and reacting the aconitic acid derivative with the phosphorus-based flame-retardant molecule to form a flame-retardant aconitic acid-derived monomer, which is then polymerized. The aconitic acid derivative can be synthesized from aconitic acid obtained from a bio-based source.

Abstract: Provided is EVOH resin pellet capable of suppressing the occurrence of fish eye even in a resultant monolayer film, and the method for producing the same. The EVOH resin pellet contains a boron compound and the boron amount in a surface portion of the pellet is 1.7 ppm or less. After the EVOH resin pellet is made to contain the boron compound, the EVOH resin pellet is rinsed with a mixture of water and alcohol so that the amount of the boron compound in a surface portion can be reduced.

Abstract: The present disclosure provides a gasket for closures made from or containing a polyolefin composition (I) made from or containing A) from about 25 to about 62% by weight of a copolymer of butene-1 with ethylene having a copolymerized ethylene content of up to about 18% by mole and without a melting peak detectable at the DSC at the second heating scan; B) from about 38 to about 75% by weight of (i) a propylene homopolymer, or (ii) a propylene copolymer, or (iii) a mixture of two or more of (i) and (ii), having a melting temperature Tm, measured by DSC at the second heating scan, of from about 130° C. to about 165° C.; wherein the amounts of A) and B) are referred to the total weight of A)+B) and the DSC second heating scan is carried out with a heating rate of about 10° C. per minute.

Abstract: The present invention relates to a film comprising at least one layer which comprises a polymer composition comprising (a) a multimodal polymer of ethylene.

Abstract: The disclosure provides an ethylene copolymer having a density of from 0.912 g/cm3 to 0.925 g/cm3, a melt flow ratio (I21/I2) of from 20 to 30, and a normal comonomer distribution profile in a GPC-FTIR analysis, wherein the normal comonomer distribution profile has a slope of from ?3.5 to ?7.5, where the slope is defined as the number of short chain branches per 1000 carbons at a molecular weight of 300,000 minus the number of short chain branches per 1000 carbons at a molecular weight of 30,000. The ethylene copolymers have improved bulk density and when made into film, provide good physical properties.

Abstract: The present invention relates to a method for producing a vinyl chloride-based resin composition which exhibits good processability due to excellent solubility in a solvent, can implement excellent transparency in products produced, and improves the glossiness of a coating film when used as an ink binder, thereby being capable of being used as a high-quality adhesive and ink binder, and a method for producing the same.

Abstract: The present invention relates to the synthesis of an associative acrylic (co)polymer by aqueous emulsion radical polymerization. The (co)polymer contains at least one oligomer of acrylic acid represented by the formula (I): where n is an integer ranging from 1 to 10. The oligomer is prepared from acrylic acid at a temperature of between 50° C. and 200° C. in the presence of a basic or acid catalyst, water, and polymerization inhibitors. The present invention also relates to the associative acrylic (co)polymer obtained from the method and also to the use of this (co)polymer as a thickener in various formulations.

Abstract: A polymeric composition comprising (i) a plurality of monomers selected from (a) a carboxylic acryloyi monomer; (b) a sulfonic acryloyi monomer; (c) an amine acryloyi monomer; (d) a hydroxyl acryloyi monomer; (e) an alkyl acryloyi monomer; and (f) a polyalkylene hydroxyl acryloyi monomer; (ii) a divalent metallic crosslinking agent; and (c) a stabilizing agent is disclosed herein. Also provided are the use of said polymeric composition as a hydrogel coating material, a method of synthesizing the polymeric composition and the use of the hydrogel material.

Abstract: This invention provides reactive, flexible, water-resistant hydroxyethylpyrrolidone methacrylate/glycidyl methacrylate copolymers, or hydroxyethylpyrrolidone methacrylate/glycidyl methacrylate/-(Methacroyloxyglyceryl-Cellulosic) block copolymers. This invention provides hydroxyethylpyrrolidone methacrylate/glycidyl methacrylate copolymers having the structure: wherein x and y are mole %, the sum equals to 100, and wherein said copolymer is prepared by precipitation polymerization. The copolymer is useful in a wide variety of compositions.

Abstract: The present invention provides a water-soluble or water-dispersible polymers. The water-soluble or water-dispersible polymer comprise a first monomer having hydrogen bonding/complexing properties to polyphenols, a second monomer having detergent properties, and a third monomer having hydrogen bonding/complexing properties to polyphenols, wherein the first monomer and the third monomer are the same or different. The present invention also provides oral care compositions comprising the water-soluble or water-dispersible polymers. The present invention also provides methods of cleaning, whitening and polishing natural teeth and dental prosthesis and of preventing, reducing or removing surface deposited stains from teeth by administering the oral care compositions. The water-soluble or water-dispersible polymer has a structure: wherein x, y, z, mole %, n, R1, and R2 are defined herein.

Abstract: The invention relates to highly biocompatible or biophilic un-cross-linked or cross-linked polymers comprising one or more side-chain active acrylic amino acids of formula I. The invention further concerns various highly biocompatible, cross-linked co-polymers comprising one or more monomers of formula I, and one or more other polymerizable monomers. Uses of such polymers and co-polymers for the production of contact lenses, intraocular lenses, implants, wound healing slabs, additives for food and cosmetics, conductive plastics, spinnable fibers, and the like are disclosed.

Abstract: The present technology relates to a polymeric material including a plurality of polymer subunits and an active cross-linker, wherein the active cross-linker is covalently linked to the plurality of polymer subunits. The active cross-linker offers a key building block for constructing novel molecular architecture in chemomechanical soft materials and illustrates a new approach to tailor material properties.

Abstract: An ethylenically unsaturated polymer includes at a terminus the radical of an allylic compound that includes a functional group free of active hydrogen atoms that is bonded to the allylic C atom through a S, P, Si or Sn atom and a vinyl aromatic compound. The polymer can be used as a component of a variety of elastomeric compounds used in the production of vulcanizates.